Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

RIGLNYSE / NASDAQHealthcareSmall cap

$40.09-$1.10 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$559.7M
P/E
1.5x
EV / EBITDA
4.4x
Revenue
$294.3M
Net margin
124.7%
ROCE
30.3%

-8.6% over the last year

Rigel Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-16.7%
3M
-11.4%
6M
+39.1%
1Y
-8.6%
5Y
Hidden
  • This period includes a one-day price step on 8 Jun 2022 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$1.10 (-2.7%) from $41 to $40 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RIGL, bought on each weekday since 2021.

News & filings

What Rigel Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity of 93.8%.

Concerns (1)

  • Operating cash flow was 0.21 times net profit in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.

Read moreShow less

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Sector
Healthcare
Shares outstanding
18.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$559.7M
P/E
1.5x
P/B
1.4x
EV / EBITDA
4.4x
EV / Sales
1.9x
P/S
1.9x
52-week high
$51.45
52-week low
$25.44

Profitability

Operating margin
42.6%
Net margin
124.7%
EBITDA margin
44.7%
ROE
93.8%
ROCE
30.3%
ROIC
32.0%
ROA
71.5%
Asset turnover
0.57

Growth

Revenue
$294.3M
Revenue growth, 1Y
64.1%
Revenue CAGR, 3Y
34.8%
Net profit growth, 1Y
1999.1%
Free cash flow
$75.7M

Solvency

Current ratio
2.42
Debt / Equity
0.14
Debt / Assets
0.10
CFO / Net profit
0.21
Cash / Market cap
7.3%

Where the revenue went

Of every $100 of FY2025 revenue, $125 was left as net income.

Rigel Pharmaceuticals, Inc. income statement flow, FY2025
Rigel Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$19.6M
RevenueGross profit$274.7M
Gross profitOperating expenses$149.2M
Gross profitOperating income$125.5M
Operating incomePretax income$121.8M
Operating incomeInterest and other expense$3.6M
Pretax incomeNet income$121.8M
Tax benefit and otherNet income$245.2M

Revenue and net profit

Revenue grew 64.1% in FY2025; net profit is the dashed line.

Rigel Pharmaceuticals, Inc. revenue and net profit by fiscal year
Rigel Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$120.2M-$58.6M
FY2023$116.9M-$25.1M
FY2024$179.3M$17.5M
FY2025$294.3M$367.0M

Cash flows

FY2025: $75.7M from operations, $75.7M free after investment (dashed).

Rigel Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Rigel Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$73.8M-$74.2M
FY2023-$5.7M-$20.7M
FY2024$31.5M$31.1M
FY2025$75.7M$75.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$294.3M+64.1%1Y
EBITDA
$131.6M+361.4%1Y
Net profit
$367.0M+1,999.1%1Y
Cash from operations
$75.7M+140.4%1Y
Free cash flow
$75.7M+143.5%1Y
Revenue CAGR, 3Y
34.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$294.3M$131.6M$367.0M$75.7M93.8%+64.1%+1999.1%

Monthly returns

Month-by-month returns of RIGL across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$513.6M
Liabilities$122.1M
Equity$391.5M
Paid-in capital$1.4B
Retained earnings-$1.0B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RIGL highlighted.

P/E against peers

RIGL trades at 1.5x earnings against a peer median of -6.4x.

  1. Rigel Pharmaceuticals, Inc. (this company)1.5x

EV / Sales, for the companies without earnings

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Rigel Pharmaceuticals, Inc.RIGLthis company$559.7M1.5x1.4x93.8%4.4x
Altimmune, Inc.ALT$567.9M-6.4x2.5x-39.2%-6.4x
Tactile Systems Technology, Inc.TCMD$567.7M29.7x2.6x8.7%12.4x
MiMedx Group, Inc.MDXG$563.0M11.6x2.2x18.9%5.3x
Ironwood Pharmaceuticals, Inc.IRWD$559.7M23.3x-2.1x-9.2%9.0x
Cytek Biosciences, Inc.CTKB$559.2M-8.4x1.6x-19.5%-28.3x
Cerus CorporationCERS$559.0M—8.7x-24.3%—
NeuroPace, Inc.NPCE$556.4M-25.9x29.2x-112.8%-50.2x
Fulgent Genetics, Inc.FLGT$553.8M-9.2x0.5x-5.4%-11.2x
Peer median—-6.4x2.4x-14.3%-6.4x

Year-to-date ROI

RIGL since 1 January, against earlier years.

Historical volatility

RIGL's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Rigel Pharmaceuticals, Inc. operating margin by fiscal year
Rigel Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY2022-45.1%
FY2023-17.5%
FY202413.5%
FY202542.6%
LineFY2025
Cost of revenueCost Of Revenue$19.6M
Gross profitGross Profit$274.7M
Operating expensesOperating Expense$149.2M
Research and developmentResearch And Development$33.3M
Selling, general and administrativeSelling General And Administration$115.9M
Total expensesTotal Expenses$168.8M
Pretax incomePretax Income$121.8M

Learn while you research

Academy chapters picked for Rigel Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 1.5 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Growth Investing64% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →